Alvotech In-Licenses Xolair Rival From BiosanaPharma

Co-Development Deal Will See Pair Collaborate On Omalizumab Biosimilar

Licensing Neon Sign Wall
The licensing deal targets a $3.3bn opportunity in Xolair • Source: kaarle dev / Alamy Stock Photo

More from Deals

More from Business